Reuter U, Goadsby P, Lanteri-Minet M, et al. Efficacy and safety of erenumab in episodic migraine patients with 2-4 prior preventive treatment failures: Results from the Phase 3b LIBERTY study. AAN 2018, emerging science abstract 009.
Rabobank investeert 3 miljoen in ALS Investment Fund
nov 2017 | Neuro-musculair